ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0882

COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Abstract Number: 0883

Multimorbidity Burden in Systemic Lupus Erythematosus: A Nationwide Study
Abstract Number: 0884

Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus
Abstract Number: 0885

SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Abstract Number: 0886

Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample
Abstract Number: 0887

Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Abstract Number: 0888

Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
Abstract Number: 0889

Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Abstract Number: 0890

Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Abstract Number: 0891

Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire
Abstract Number: 0892

Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
Abstract Number: 0893

Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years
Abstract Number: 0894

Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Abstract Number: 0895

Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Abstract Number: 0896

Systemic Lupus Erythematosus Disease Flares After SARS-CoV-2 Vaccination

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].